Long-term efficacy of alemtuzumab in polymyositis.
Ruck T; Bittner S; Kuhlmann T; Wiendl H; Meuth SG
Other scientific publication | Peer reviewedAbstract
We present a PM patient refractory to standard therapy, who showed effective clinical remission after a single treatment cycle with alemtuzumab for >3 years of follow-up. This is, to our knowledge, the first report of long-term efficacy of alemtuzumab in the treatment of PM
Details about the publication
Status: Published
Release year: 2015 (28/03/2015)
Language in which the publication is written: English
Link to the full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC4334687/
Keywords: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Neoplasm; CD52 Antigen; Follow-Up Studies; Glycoproteins; Humans; Male; Middle Aged; Polymyositis; Time Factors; Treatment Outcome
Authors from the University of Münster
| Bittner, Stefan | |
| Meuth, Sven | |
| Ruck, Tobias | |
| Wiendl, Heinz Siegfried |